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z.2012.10Abstract The genotoxic effects of actinomycin D (ActD) were assayed in an in vivo test utilizing
bone marrow cells and serum protein electrophoresis assay. ActD (0.0005%) was dissolved in
0.9% saline and administered intraperitoneally at a volume of 1 ml solution per 100 g body weight.
Five groups of male mice, were intraperitoneally injected with ActD and were sacriﬁced after 2, 6,
24, 36 and 48 h. The number of the micronucleated cells increased gradually with increasing sam-
pling time from 2 to 36 h. At 48 h the micronuclei frequencies in bone marrow cells of the treated
animals were still elevated when compared to the MN frequency in the control mice. No signiﬁcant
difference in the polychromatic erythrocytes (PCEs) percentage, normochromatic erythrocytes
(NCEs) percentage and PCEs/NCEs ratio was found in all the treated groups compared to the con-
trol. The electrophoretic patterns of serum protein showed great changes in shape, number and
intensities of the protein bands.
ª 2012 The Egyptian German Society for Zoology. Production and hosting by Elsevier B.V. All rights
reserved.Introduction
The therapeutic effect of actinomycin D (ActD) was reported
by several authors. Lurain (2002) treated successfully gesta-
tional trophoblastic tumors with ActD. Miyazaki et al.
(2003) demonstrated the limited efﬁcacy of methotrexate,
ActD and cisplatin as a salvage therapy for patients with met-
astatic testicular cancer. Damian et al. (2006) concluded thato.com
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.001regional chemotherapy with the isolated limb infusion (ILI)
technique using melphalan and ActD reduced disease bulk,
and restored the limb to normal function within a few weeks.
Although not curative, ILI could be an effective adjunctive
treatment for severe chromomycosis in patients resistant to
or intolerant of other therapies. Li et al. (2006) showed that
both preoperative transcatheter arterial chemoembolization
(TACE) and conventional preoperative chemotherapy with
vincristine (VCR); ActD plus lipiodol-Epirubicin (EPI) could
be applied to the patients with advanced Wilms’ tumor who
were not candidates for immediate surgical resection.
Hannachi Sassi et al. (2008) treated successfully four-year-old
and 12-month-old boys suffering from clear cell sarcoma of
the kidney by surgery and chemotherapy that included ActD.
Wang et al. (2008) suggested that a novel ActD analog
leu5AMD may be used as a promising chemotherapeuticaland hosting by Elsevier B.V. All rights reserved.
250 I.A.E. Darwishagent for patients affected by gastric carcinoma and other solid
cancers.
Madle et al. (1976) showed that actinomycin D (inhibitor of
RNA synthesis) did not lead to a signiﬁcant suppression of the
frequencies of mitoses with micronucleus derived premature
chromosome condensation in human leukocyte cultures. Hart
and Hartley-Asp (1983) did not ﬁnd a signiﬁcant effect on the
incidence of micronuclei in mouse bone morrow erythrocytes 6
and 24 h after a single intraperitoneal treatment with actino-
mycin D. Tagawa et al. (1987) suggested that actinomycin D
had an inhibitory action on the cell cycle, accompanied with
a marked decrease in RNA content of the cultured cancer cells
(PCI). Mozdarani and Saberi (1994) stated that the frequency
of radiation-induced micronucleated polychromatic erythro-
cytes (MNPCEs) in the presence of ActD was not much higher
than that resulted by ActD alone.
Chakrabarti et al. (2001) stated that actinomycin D had
genotoxic effects of its own and also had additive effects on
sonication-induced genotoxicity in mice using parameters like
chromosome aberrations (CA), mitotic index (MI), sperm
head anomaly (SHA) and micronucleated erythrocytes
(MNEs).
Ho et al. (2008) suggested that perturbation in chromosome
binding proteins in mitotic cells by actinomycin D could affect
their function in regulating mitotic progression, thus leading to
severe spindle defects and mitotic catastrophe. Hashimoto
et al. (2010) considered that the frequency of large-size micro-
nuclei in the in vitro micronucleus assay is an alerting index for
aneugenic effects which is as effective as the immunoﬂuores-
cence staining method for discrimination of aneugens from
clastogens (ActD).
The effect of this chemotherapeutic agent on protein is re-
viewed by several authors. Accordingly, Cooper and Burgess
(1984) revealed major changes in the biosynthetic rates for
16 proteins after treatment with actinomycin D in myelomon-
ocytic leukemia cell line (WEHI-3B (D+)) using gel
electrophoresis.
An attempt was made in this study to determine the clasto-
genic potential of ActD in mice using micronucleus test and
serum protein electrophoresis assay.
Materials and methods
Chemical
Actinomycin-D (ActD), composed of 0.5 mg dactinomycin
and 20 mg mannitol, was used; this is commercially available
as Lyovac Cosmegen (Merck). After dilution with physio-
logic saline, 0.0005% of ActD was injected intraperitoneally
at a ﬁnal volume of 1 ml/100 g body weight. This dose was
chosen according to Chakrabarti et al. (2001). It was
prepared by dissolving 500 lg of ActD in 100 ml distilled
water.
Animals
Male mice aged 6–8 weeks old (25 ± 5 g) were used. Five
groups of mice, were intraperitoneally injected with ActD
and were sacriﬁced after 2, 6, 24, 36 and 48 h. The control mice
were injected with distilled water. Six animals were used for
each treated group.Micronucleus (MN) test
The mice were killed at various times after a single treatment
as mentioned above. Bone marrow smears were prepared as
described by Agarwal and Chauhan (1993), stained with Giem-
sa, and the incidence of micronuclei in polychromatic (PCEs)
and normochromatic (NCEs) erythrocytes was counted and
the PCEs/NCEs ratios were scored (1000 PCEs/animal).
Polyacrylamide gel-electrophoresis (SDS–PAGE) for serum
protein analysis
Blood was collected from retro-orbital plexus into serum sep-
aration tubes, allowed to clot for 30 min at room temperature
followed by centrifugation (1000·g, 10 min, 4 C). The serum
samples were stored at 70 C. The SDS–PAGE was per-
formed according to the method described by Stegemann
et al. (1988) using 1 mm thick gel. The gel was stained with
Coomassie Brilliant Blue R-250 stain. After de-staining, the
gel was scanned using Helenu photoscanner and integrated
using the corresponding computer software.
Statistical analysis
The signiﬁcance was evaluated using one way analysis of var-
iance (ANOVA test). In cases where ANOVA showed signiﬁ-
cant differences, post hoc analysis LSD was performed. P
values less than or equal to 0.05 were considered statistically
signiﬁcant.
Results
The micronucleus assay
The clastogenicity of ActD has been investigated using the
bone marrow micronucleus assay. The control group – with
saline treatment – showed a range of 0–5 micronucleated cells
per 1000 PCEs/animal. The incidence of micronuclei in poly-
chromatic erythrocytes was 16, 19 and 20/6000 PCEs in the
control, 2 and 6 h groups, respectively (Table 1 and Fig. 1).
The highest induction was obtained 36 h after treatment with
actinomycin D (7.33 ± 2.16/6000 PCEs). A signiﬁcant in-
crease in the percentage of micronucleated cells over that of
the control was observed 36 h after i.p. injection with ActD.
This value was decreased to 3.83 ± 0.75 after 48 h exposure.
Most of the cells had one micronucleus but a few cells with
two or three micronuclei were also encountered (Fig. 2). The
percentage of PCEs and the ratio of PCEs to NCEs were grad-
ually increased until 24 h; then decreased slightly and reached
minimum values at 48 h. No signiﬁcant variation of either
PCEs % or the relative ratio of the PCEs to NCEs was ob-
served. Also, the percentage of NCEs was gradually increased
after treatment with ActD until 24 h as compared to the vehi-
cle controls, though this increase was not signiﬁcant on the sta-
tistical level.
Protein bands electrophoresis
Scanning of Sodium Dodecyl Sulfate Polyacrylamide Gel
Electrophoresis (SDS–PAGE) of mice serum proteins in the
Table 1 The incidence of micronucleated polychromatic erythrocytes in bone marrow cells of mice treated with actinomycin D.
Hours Small MN Large MN More than one MN Total Mean ± S.D. % MN % PCEs % NCEs PCEs/NCEs
0 12 – 4 16 2.67 ± 1.75. 0.27 4.8 5.2 0.92
2 18 1 – 19 3.17 ± 1.17n.s. 0.32n.s. 5.13n.s. 4.86n.s. 1.05n.s.
6 19 – 1 20 3.33 ± 1.508n.s. 0.33n.s. 5.28n.s. 4.71n.s. 1.12n.s.
24 31 – 4 35 5.67 ± 1.638a1,a2,a3,a4 0.58n.s. 5.36n.s. 4.63n.s. 1.15n.s.
36 35 – 9 44 7.33 ± 2.16b 0.73n.s. 4.36n.s. 5.63n.s. 0.77n.s.
48 20 2 1 23 3.83 ± 0.75n.s. 0.38n.s. 4.05n.s. 5.95n.s. 0.68n.s.
% MN, micronucleated cell percentage; % PCEs, polychromatic erythrocytes percentage; % NCEs, normochromatic erythrocytes percentage;
PCEs/NCEs ratio, the ratio of PCEs to NCEs; a1, 24 h highly signiﬁcant from control (P< 0.01); a2, 24 h signiﬁcant from 2 h (P< 0.01); a3,
24 h highly signiﬁcant from 6 h (P< 0.01); a4, 24 h signiﬁcant from 48 h (P< 0.05); b, 36 h highly signiﬁcant from 48 h (P< 0.001); n.s., non
signiﬁcant from any other group by using one way ANOVA.
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Figure 1 Effect of actinomycin D on micronucleated cells in the bone marrow of mice.
Figure 2 Bone marrow micronucleated cells in mice due to treatment with actinomycin D: (a) a small micronucleus, (b) a large
micronucleus and (c) more than one micronucleus.
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molecular weights of which ranged from 291.54 to 10 kilodal-
ton (kDa). The data presented in Table 2 showed that the total
number of bands in control and samples treated with ActD
were 21, 20, 20, 20, 23 and 20, respectively. The numbers of
the added new bands were 4, 4, 7, 6 and 5 after 2, 6, 24, 36
and 48 h, respectively. On the contrary to that, the highest
number of lost bands was recorded after 24 h, being 8 if com-
pared with the control bands.
Three types of protein were recorded as common types in the
tested samples with RF that ranged between 0.16 and 0.76 andmolecular weights of 139.23 and 31.897 kDa, respectively. The
band numbers 2, 3, 6, 8, 9, 11, 12, 18, 27 and 29 are considered
as themajor protein constituents since they are commonly found
with high relative concentrations in the control mice and in all
the treatments. Some fractions disappeared completely or
shifted to other positions with percentages lower or higher than
those of the control mice serum (Figs. 3 and 4).
During the course of exposure some bands exhibited an in-
crease in their relative percentages (8), while others showed a
remarkable decrease in their relative percentages (1, 3, 12
and 29).
Table 2 Molecular weight, RF and band percentages for Mus musculus treated with actinomycin D.
Rows Lanes
Control 2 h 6 h 24 h 36 h 48 h
Mol. wt. RF B% Mol.
wt.
RF B% Mol.
wt.
RF B% Mol.
wt.
RF B% Mol.
wt.
RF B% Mol.
wt.
RF B%
r1 291.54 0.013 2.06 286.92 0.017 1.37 277.69 0.026 0.916 286.92 0.017 1.53 286.92 0.017 0.914
r2 268.46 0.035 3.39 254.62 0.048 3.47 254.62 0.048 3.19 259.23 0.043 4.16 263.85 0.039 5.46 263.85 0.039 4.22
r3 194.62 0.1 7.25 194.62 0.1 6.52 194.62 0.1 6.6 194.62 0.1 4.42 203.85 0.096 4.12 203.85 0.096 4.77
r4 153.08 0.14 3.48 171.54 0.13 3.12 176.15 0.12 3.47
r5 139.23 0.16 3.66 139.23 0.16 3.28 139.23 0.16 4.4 134.62 0.16 3.37 139.23 0.16 3.7
r6 124.23 0.19 4.06 123.08 0.19 4.25 124.23 0.19 3.78 120.77 0.2 4.3 123.08 0.19 2.57 124.23 0.19 3.64
r7 113.85 0.23 2 117.31 0.21 1.43
r8 104.62 0.26 2.06 110.38 0.24 2.7 109.23 0.24 3.01 109.23 0.24 3.28 111.54 0.23 2.51 111.54 0.23 2.88
r9 97.692 0.29 2.56 101.15 0.27 2.53 98.846 0.28 3.06 96.538 0.29 2.52 97.692 0.29 4.13 98.846 0.28 3.85
r10 93.077 0.3 1.06
r11 86.154 0.33 7.52 90.769 0.31 5.71 90.769 0.31 8.35 90.769 0.31 4.69 89.615 0.32 6.8 89.615 0.32 2.02
r12 75.769 0.37 6 79.231 0.36 3.18 81.538 0.35 3.08 80.385 0.35 2.36 76.923 0.37 3.72 79.231 0.36 4.06
r13 71.154 0.39 5.43 72.308 0.38 4.8 68.636 0.4 6.71
r14 64.545 0.43 7.32 63.864 0.43 8.43 63.182 0.43 8.76 65.227 0.42 6.53 65.909 0.42 8.69
r15 58.409 0.47 8.6 59.091 0.46 4.17
r16 54.259 0.5 15.1
r17 52.037 0.52 17.3 51.296 0.53 14.8 51.667 0.53 14.1 52.778 0.51 21 52.778 0.51 12.5
r18 47.222 0.58 3.79 46.481 0.59 3.45 46.852 0.58 4.42 46.852 0.58 3.42 46.481 0.59 3.43 46.111 0.59 4.85
r19 44.259 0.61 2.55 43.519 0.62 2.65 43.519 0.62 2.55 43.519 0.62 2.61
r20 42.407 0.63 3.05 42.778 0.63 4.62 42.037 0.64 2.61
r21 41.296 0.65 4.87 41.296 0.65 3.67 39.444 0.67 4.67 40.556 0.66 3.59 39.815 0.67 3.12
r22 37.963 0.69 2.83 36.111 0.71 2.69 36.481 0.7 1.91
r23 33.621 0.74 4.24 35.37 0.72 2.04 35.741 0.71 2.63
r24 31.897 0.76 9.99 32.586 0.75 4.57 31.897 0.76 8.9 30.517 0.78 5.88 31.897 0.76 4.74
r25 29.483 0. 79 2.01 27.414 0.82 2.4 27.414 0.82 3.06 28.448 0.8 2.65
r26 27.069 0.82 4.27 26.379 0.83 3.6
r27 22.273 0.87 6.58 20.909 0.89 7.26 20.455 0.89 6.54 21.818 0.88 4.58 21.364 0.88 4.84 20.455 0.89 3.38
r28 14.167 0.95 2.54 15 0.94 4.92 14.167 0.95 2.95
r29 10 0.97 5.59 10 0.97 4.87 8.3333 0.97 3.94 8.333 0.97 3.44 9.1667 0.97 3.92 10 0.97 4.58
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Figure 3 Gel represents serum protein pattern ofMus musculus after treatment with actinomycin D. Lanes from left to right, respectively:
M, high molecular weight marker; lane 1, control; lanes 2–6, mice treated with 0.0005% ActD for 2, 6, 24, 36 and 48 h, respectively.
The genotoxic effect of actinomycin D on micronuclei of bone marrow cells 253The band number 16 was detected only after 48 h with mol.
wt. 54.259 and RF 0.5. In contrast, the band numbers 14 and
17 were absent after 24 and 48 h with mol. wt. 64.545 and
52.037 kDa and RF 0.43 and 0.52, respectively.
The similarity index between the control and 2, 6, 24, 36
and 48 h treated samples was 0.780, 0.780, 0.634, 0.772 and
0.731, respectively. The smallest similarity index was between
mice treated for 24 h and the control group, while the highest
was between mice treated for 24 and 36 h (Table 3).
On the other hand, the genetic distance ranged from 0.22 to
0.366 in the control and treated samples, respectively, while it
ranged from 0 to 0.25 in the treated samples. The lowest con-
centration for the genetic distance was recorded in mice treated
for 36 h and 24 h. Furthermore, the highest level of quantita-
tive mutation appeared in the protein of 89.615 kDa which de-
creased to 3.722 after 48 h of treatment with ActD as
compared with the untreated mice.Discussion
Little is known about the pharmacokinetics of ActD in
humans, despite its long history of clinical use, largely due to
problems in developing an analytical assay with the required
sensitivity to measure relevant clinical concentrations (Veal
et al., 2003).
In the current study, ActD was tested for potential genotox-
icity in male mice. The mice were then assessed at different
intervals, against suitable control, using the incidence of
micronucleated erythrocytes and serum protein electrophoresis
assay as the end points.
An increase in the micronucleus frequency did not occur
until 6 h post-treatment, presumably as a result of cell cycle
elongation or mitotic delay. However, the frequency of micro-nucleated PCEs increased between 2 and 36 h, then decreased
rapidly and reached a minimum level at 48 h.
The increase of micronucleated cells after 36 h of treatment
observed in the present study might be due to the residual
effect of ActD or its toxic metabolites. The increasing yield
of MN with time due to treatment with the chemotherapeutic
agent in the present study is consistent with the report of
Chakrabarti et al. (2001) for MN induction in PCEs of bone
marrow cells.
The observed lower MNPCEs frequencies after 48 h of
treatment with ActD, accompanied by reduced bone marrow
toxicity, might reﬂect a drug-related adaptative reaction of
the animals, for example the induction of detoxifying enzymes.
The ﬁndings of the present study are in accordance with the
other mutagenicity testing protocols reporting ActD as a weak
and/or a positive mutagen (Chakrabarti et al., 2001).
Most of the cells had one micronucleus, but a few cells with
large-size micronuclei were also encountered. The increased
frequency of small micronucleated cells reﬂects damage by
ActD which causes chromosome breakage or non-disjunction.
The antibiotic actinomycin D has been shown to induce
chromosomal lesions in mammals’ interphase cells
(Chakrabarti et al., 2001; Ohe et al., 2002; Chaudhuri et al.,
2006; Gowans et al., 2007; Spano et al., 2007; Ho et al.,
2008; Ho and Li, 2010). In the present study, ActD induced
a slightly clastogenic activity in vivo. This discrepancy may
imply that the mutagenic species produced in the whole animal
do not reach the bone marrow in sufﬁcient concentration if at
all (Mozdarani and Saberi, 1994). This conclusion is supported
by Bruce and Heddle (1979) who tested the genotoxic effect
of ActD after a 5-dose-treatment regimen at doses up to
10 mg/kg. This compound did not produce a signiﬁcant effect
on the incidence of micronucleated PCEs. They found a
positive effect at the top dose level.
Figure 4 Electropheogram and photomicrograph of gel representing the variation in serum protein pattern of Mus musculus after 2, 6,
24, 36 and 48 h of treatment with the chemotherapeutic agent. Lanes 1–6: mice treated with 0.0005% ActD for 2, 6, 24, 36 and 48 h,
respectively.
Table 3 The similarity index and genetic distance based on
SDS–PAGE of serum protein data of the mice, Mus musculus
treated with 0.0005% actinomycin D for 2, 6, 24, 36 and 48 h.
Treatment Control 2 h 6 h 24 h 36 h 48 h
Control – 0.780 0.780 0.634 0.772 0.731
2 h 0.22 – 0 0.80 0.790 0.75
6 h 0.22 0 – 0.80 0.790 0.75
24 h 0.366 0.20 0.20 – 0.837 0.75
36 h 0.228 0.21 0.21 0.163 – 0.790
48 h 0.269 0.25 0.25 0.25 0.21 –
254 I.A.E. DarwishHowever, the mean relative number of NCEs was slightly
increased after treatment for 36 and 48 h as compared to the
mean values of NCEs of the corresponding vehicle controls,
indicating that ActD had weak cytotoxic properties on thebone marrow cells. In the present study, the PCEs/NCEs ratio
ranged between 0.68 and 1.15. The relative ratio of the PCEs
and NCEs in all experimental groups was not signiﬁcantly dif-
ferent, which suggests that the frequency of formation of the
two types of erythrocytes was almost equal. It also implies that
the process of erythrocyte formation was not affected by the
ActD treatment.
The timing of the ﬁnal stages of mouse bone-marrow eryth-
ropoiesis has been determined by Cole et al. (1981) as roughly
10 h from the ﬁnal mitosis to the expulsion of the nucleus from
an orthochromatic erythroblast to produce a polychromatic
erythrocyte. Estimates of the cell-cycle parameters are G1
1.0 h, S 7.5 h, G2 1.5 h. On the bases of these times, a clastogen
acting in S phase should not show any effect before at least
1.5 + 10 h after treatment. This is consistent with the results
obtained by Bacchetti and Whitmore (1969) who observed
variations in sensitivity to actinomycin D during the division
The genotoxic effect of actinomycin D on micronuclei of bone marrow cells 255cycle of synchronized populations of mouse L cells in the S
phase that showed the greatest uptake of the drug and also
the greatest sensitivity.
Under the effect of ActD, a wide spectrum of serum protein
variations was recorded in terms of component mobilities and
concentrations, i.e. new proteins appeared, some disappeared
and some others varied in concentration. No generalization
concerning the trend of electrophoretic protein variations of
the serum of mice can be given. The present study showed that
some of the proteins added to the original pattern were in the
middle and low molecular weight areas of the gel. The appear-
ance of new bands in the low molecular weight areas assumes
that the low molecular weight proteins were more sensitive to
ActD treatment.
Schnell and Chiang (1990) suggested that these changes may
have resulted from the formation of adductus between proteins
of the serum and the chemotherapeutic agent itself. Aly and
Shaurub (1997) presumed that the appearance of new protein
bands after irradiation with gamma rays was probably due to
the presence of free radical which affects directly the nitroge-
nous compounds. Such effect leads to the breakdown of the
peptide linkage causing fragmentation of protein. Rady
(1997) proposed that the new build of protein fractions in the
serum proteins under different stress conditions reﬂects that
there is an extensive liberation of the enzyme into the circula-
tion. In the author’s opinion, it might be concluded that the
variation in protein bands may depend – among other factors
– on the mode of action of the compound applied.
These results suggest that ActD induced higher frequencies
of micronucleated cells, accompanying a change in serum pro-
tein. Further studies are needed for elucidating mechanisms of
the genotoxic actions of ActD and for evaluating their poten-
tial hazards to the human health.
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